KALV is currently developing the following drugs: Kvd900 600 Mg, Kvd900 300 Mg, Kvd900 150 Mg, Kvd900 600 Mg, Kvd900 300 Mg, Kvd900 600 Mg, Drug: Kvd900 300 Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.